Pharmaxis Ltd
Unit 2, 10 Rodborough Road
Frenchs Forest
New South Wales
2086
Tel: 61-2-9451-5961
Fax: 61-2-9451-3622
Website: http://www.pharmaxis.com.au/
Email: info@pharmaxis.com.au
About Pharmaxis Ltd
Pharmaxis is a specialist pharmaceutical company committed to the research, development and commercialisation of human therapeutic products that improve the clinical management of chronic respiratory and autoimmune diseases.Pharmaxis has a diversified portfolio of products at various stages of development which target attractive international markets across a range of diseases.
AridolTM: addresses a new market - providing a clinical management tool for asthma and COPD. It is scheduled to complete Phase III clinical trials in Q3 of 2004, with the initial product launch scheduled for Q3 of 2005.
BronchitolTM: a new therapeutic targeting cystic fibrosis, bronchiectasis, and chronic bronchitis. It is scheduled to complete Phase II clinical trials in H2 of 2004, with Phase III clinical trials scheduled to commence in H1 of 2005. The initial product launch is scheduled for CY 2008
PXS25: inhibits immune cell trafficking and is being developed for the treatment of multiple sclerosis and other autoimmune diseases.
PXS2000: represents a new class of anti-inflammatory agent under development for rheumatoid arthritis. Pharmaxis is building a fully integrated specialist pharmaceutical company with activities spanning research and development through to manufacture, marketing, and distribution.
The company's board of directors and senior management team has extensive experience in developing and commercializing successful breakthrough products.
Last Updated: 05-20-04
125 articles about Pharmaxis Ltd
-
FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer
11/9/2021
Clinical stage drug development company Pharmaxis Ltd announced that an Investigational New Drug application for a trial of PXS-5505 in hepatocellular carcinoma patients has been cleared by the United States Food and Drug Administration.
-
Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial
10/5/2021
Clinical stage drug development company Pharmaxis Ltd announced further positive results of data analysis from a phase 1c clinical trial studying its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis for 28 days at three dosage levels.
-
Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial
8/31/2021
Pharmaxis announced that its novel topical drug treatment for scarring has delivered positive Phase 1 clinical trial results and will now advance to the next stage of development in patients.
-
Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model
8/5/2021
Clinical stage drug development company Pharmaxis Ltd announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma at the Americas Hepato-Pancreato-Biliary Association conference in Miami, USA.
-
Pharmaxis Commences Final Cohort Dosing in Bone Marrow Cancer Phase 1c Trial
8/4/2021
Clinical stage drug development company Pharmaxis Ltd announced results of data analysis from the second of three stages in its phase 1c clinical trial studying a potential new treatment for the bone marrow cancer myelofibrosis.
-
FDA Bronchitol Approval to Generate Cash Flows for Pharmaxis
11/2/2020
It is the gold standard of success in biotech, but not many Australian companies can boast it – approval from the United States Food & Drug Administration of a medicine you have researched and developed.
-
EffRx Pharmaceuticals Signs Exclusive License Agreement with Pharmaxis for the Registration and Commercialization of Bronchitol® in Switzerland
6/13/2019
The product is inhaled as dry powder twice daily using a small handheld device and it is expected to be available on the Swiss market by 2021.
-
Synairgen announces positive progress on LOXL2 programme by Pharmaxis
1/17/2019
Synairgen (LSE: SNG), the respiratory drug discovery and development company, is pleased to note that Pharmaxis has reported receipt of all data for the LOXL2 inhibitor candidates in three-month toxicity studies.
-
Pharmaxis releases positive results of Phase 1 clinical trial for second LOXL2 inhibitor compound
11/15/2018
Arix Bioscience plc is pleased to note that Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis, has announced positive results from the Phase 1 clinical trial for the second of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF).
-
Arix Bioscience announces first VIPE investment
8/6/2018
Arix Bioscience plc (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announces that it has acquired an 11 per cent interest in Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval.
-
Pharmaxis Boehringer Ingelheim Is Initiating Phase Iia Study For The Development Of A New Treatment For Diabetic Retinopathy - A Leading Cause Of Vision-Loss
9/8/2017
-
Boehringer Ingelheim Initiates Phase IIa Study Of Compound Acquired From Pharmaxis In Debilitating Liver Disease NASH
8/25/2017
-
Pharmaxis Releases Successful Results Of Phase 1 Clinical Trial For Boehringer Ingelheim Partnered Drug PXS-4728A
9/22/2015
-
Pharmaxis And Synairgen plc Announce Research Collaboration To Develop LOXL2 Inhibitor For Pulmonary Fibrosis
8/5/2015
-
Pharmaxis Shares Catapult on $750 Million Liver Drug Sale to Boehringer Ingelheim
5/18/2015
-
Boehringer Ingelheim Acquires Pharmaxis’ Phase 1 Anti-Inflammatory Drug Candidate
5/18/2015
-
Pharmaxis Ltd Slashes 30 Pct. of Jobs
5/28/2013
-
Pharmaxis Ltd Chief Steps Down in Shake-Up
3/12/2013
-
Pharmaxis Ltd Reels After Verdict on Key Drug, Bounces Back With $40 Million in Pocket
1/31/2013
-
Pharmaxis Ltd Receives Approval to Market Bronchitol in the EU
4/27/2012